METHOD FOR EYELID RETRACTION ELIMINATION DURING ENDOCRINE OPHTHALMOMYOPATHY Russian patent published in 2017 - IPC A61F9/00 A61K38/16 A61P27/02 

FIELD: medicine.

SUBSTANCE: method involves injection of type A botulinum toxin into the muscles complex that raises the upper eyelid. The lower eyelid retractor is additionally exposed to type A botulinum toxin injections. At that, the female patients with total eyelid retraction less than 2.5 mm are injected 25 units (U) of "Dysport" or 10 units of "Botox" product formulation, or "Lantox" or "Xeomin". At total eyelid retraction from 2.5 to 4 mm, 30 U of "Dysport" or 12 U of "Botox", or "Lantox", or "Xeomin" are introduced. At total eyelid retraction more than 4 mm, 35 U of "Dysport" or 14 U of "Botox", or "Lantox", or "Xeomin" are introduced. And the male patients with total eyelid retraction less than 2.5 mm are injected 35 units (U) of "Dysport" or 14 units of "Botox" product formulation, or "Lantox", or "Xeomin". At total eyelid retraction from 2.5 to 4 mm, 45 U of "Dysport" or 18 U of "Botox", or "Lantox", or "Xeomin" are introduced. At total eyelid retraction more than 4 mm, 50 U of "Dysport" or 20 U of "Botox", or "Lantox", or "Xeomin" are introduced. For men and women, the selected drug dose is divided into two equal parts. One part is introduced into the upper conjunctival vault region in the upper eyelid levator projection, by three equal portions along the pupillary line, medially and laterally at a distance of 0.5 cm, to a depth of 0.5-1.0 cm, and the other part - in the lower conjunctival vault region in the lower eyelid retractor projection, similarly.

EFFECT: versions of the invention eliminate the causes of upper and lower eyelid retraction with decreased method trauma, dosage effect is obtained, depending on the severity of the total eyelid retraction and patient's gender.

2 cl, 2 dwg, 6 ex